Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for REGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 30.23%
March 31, 2026 20.17%
December 31, 2025 21.74%
September 30, 2025 38.89%
June 30, 2025 37.86%
March 31, 2025 26.70%
December 31, 2024 24.22%
September 30, 2024 36.03%
June 30, 2024 40.38%
March 31, 2024 22.96%
December 31, 2023 33.77%
September 30, 2023 29.97%
June 30, 2023 30.66%
March 31, 2023 25.86%
December 31, 2022 35.06%
September 30, 2022 44.81%
June 30, 2022 29.82%
March 31, 2022 32.83%
December 31, 2021 45.01%
September 30, 2021 47.27%
June 30, 2021 60.31%
March 31, 2021 44.10%
December 31, 2020 47.43%
September 30, 2020 36.71%
June 30, 2020 45.97%
Date Value
March 31, 2020 34.16%
December 31, 2019 42.50%
September 30, 2019 38.40%
June 30, 2019 12.24%
March 31, 2019 33.59%
December 31, 2018 42.56%
September 30, 2018 35.75%
June 30, 2018 34.29%
March 31, 2018 31.62%
December 31, 2017 10.97%
September 30, 2017 25.88%
June 30, 2017 26.38%
March 31, 2017 18.87%
December 31, 2016 20.63%
September 30, 2016 21.70%
June 30, 2016 16.18%
March 31, 2016 15.10%
December 31, 2015 14.12%
September 30, 2015 18.50%
June 30, 2015 19.49%
March 31, 2015 8.74%
December 31, 2014 13.73%
September 30, 2014 10.98%
June 30, 2014 13.93%
March 31, 2014 10.46%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 12.74%
Gilead Sciences, Inc. -134.2%
AbbVie, Inc. 21.21%
Vertex Pharmaceuticals, Inc. 32.89%
Amgen, Inc. 23.59%